PMID- 24186136
OWN - NLM
STAT- MEDLINE
DCOM- 20141224
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 27
IP  - 5
DP  - 2014 May
TI  - Outcome of patients with micropapillary urothelial carcinoma following radical 
      cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
PG  - 758-64
LID - 10.1038/modpathol.2013.201 [doi]
AB  - Micropapillary urothelial carcinoma exhibits amplification of the human epidermal 
      growth factor receptor, ERBB2(HER2), and overexpression of the ERBB2 protein 
      product. The clinical significance of this has yet to be established. The 
      objective of this study was to examine ERBB2 amplification and protein expression 
      in micropapillary urothelial carcinoma and stage-matched typical urothelial 
      carcinoma treated by radical cystectomy to assess the frequency of amplification 
      and protein expression, and to determine the association with cancer-specific 
      survival. Pathologic material and data from patients undergoing cystectomy at 
      Mayo Clinic between 1980 and 2008 were reviewed. ERBB2 amplification by 
      fluorescence in situ hybridization (FISH) and protein expression by 
      immunohistochemistry were assessed. Univariate and multivariate Cox proportional 
      hazards regression models were used to evaluate for associations of ERBB2 
      amplification and protein expression with survival. ERBB2 amplification was 
      identified in 9 (15%) of 61 micropapillary carcinomas compared with 9 (9%) of 100 
      urothelial carcinomas. In patients with micropapillary carcinoma, ERBB2 
      amplification was associated with a nearly threefold increased risk of cancer 
      death. ERBB2 amplification (hazard ratio 4.3; P=0.0008) remained associated with 
      an increased risk of death from bladder cancer among patients with micropapillary 
      urothelial carcinoma on multivariate analysis. The association of cancer-specific 
      survival and ERBB2 amplification was not seen in patients with urothelial 
      carcinoma. ERBB2 immunohistochemistry correlated with ERBB2 amplification but 
      there was no association of ERBB2 protein expression and survival. ERBB2 
      amplification is more frequent in micropapillary urothelial carcinoma than 
      typical urothelial carcinoma, and patients with micropapillary carcinoma who have 
      ERBB2 amplification have worse cancer-specific survival than those who do not. 
      Identification of ERBB2 amplification in micropapillary carcinoma could provide 
      important prognostic information and possibly provide a role for ERBB2 targeted 
      therapy.
FAU - Schneider, Steven A
AU  - Schneider SA
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Sukov, William R
AU  - Sukov WR
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
FAU - Frank, Igor
AU  - Frank I
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Boorjian, Stephen A
AU  - Boorjian SA
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Costello, Brian A
AU  - Costello BA
AD  - Internal Medicine (Urologic Oncology), Mayo Clinic, Rochester, MN, USA.
FAU - Tarrell, Robert F
AU  - Tarrell RF
AD  - Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Thapa, Prabin
AU  - Thapa P
AD  - Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Houston Thompson, R
AU  - Houston Thompson R
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Tollefson, Matthew K
AU  - Tollefson MK
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Jeffrey Karnes, R
AU  - Jeffrey Karnes R
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Cheville, John C
AU  - Cheville JC
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131101
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Papillary/genetics/pathology/*surgery
MH  - Carcinoma, Transitional Cell/genetics/pathology/*surgery
MH  - Cystectomy
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/genetics/pathology/*surgery
MH  - Urothelium/*pathology
EDAT- 2013/11/05 06:00
MHDA- 2014/12/30 06:00
CRDT- 2013/11/05 06:00
PHST- 2013/08/20 00:00 [received]
PHST- 2013/09/10 00:00 [revised]
PHST- 2013/09/15 00:00 [accepted]
PHST- 2013/11/05 06:00 [entrez]
PHST- 2013/11/05 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - S0893-3952(22)03590-6 [pii]
AID - 10.1038/modpathol.2013.201 [doi]
PST - ppublish
SO  - Mod Pathol. 2014 May;27(5):758-64. doi: 10.1038/modpathol.2013.201. Epub 2013 Nov 
      1.